# Joel Schneider

> Joel Schneider is the founder, president and CEO of Carbon Biosciences, a Waltham, Massachusetts biotech building gene therapies from parvovirus-derived vectors rather than the more common adeno-associated viruses. He launched the company out of stealth in 2022 with a $38 million Series A led by Agent Capital, pairing his operating background with the science of gene therapy pioneer Robert Kotin. Trained as a stem cell biologist with a Rutgers Ph.D. and a Harvard postdoc, Schneider was the first employee at Solid Biosciences before founding Carbon to push vectors that carry larger genetic payloads, target specific tissues such as the lung, and sidestep the pre-existing immunity that limits current gene therapies. Carbon's lead program targets cystic fibrosis.

- **Role:** Founder, President and CEO at Carbon Biosciences
- **Organizations:** Carbon Biosciences, Solid Biosciences
- **Nationality:** American
- **Education:** Undergraduate degree, Brandeis University, Ph.D., Rutgers University, Postdoctoral fellowship, Harvard University, Department of Stem Cell and Regenerative Biology
- **Known for:** Founded Carbon Biosciences and raised a $38 million Series A to build a non-AAV, parvovirus-based gene therapy platform, Was the first employee at Solid Biosciences and helped build its disease-focused gene therapy business model, Assembled a syndicate including Agent Capital, Longwood Fund, Astellas Venture Management, the Cystic Fibrosis Foundation, Solasta Ventures, UTokyo IPC and Camford Capital

## Career timeline

- **circa 2013** — Completed postdoctoral fellowship at Harvard studying small molecules that enhance skeletal muscle regeneration
- **2013** — Became the first employee at Solid Biosciences, helping build its disease-focused business model, later serving as Chief Operating Officer
- **2022** — Founded Carbon Biosciences and became President and CEO
- **2022** — Led Carbon Biosciences out of stealth with a $38 million Series A financing led by Agent Capital
- **2024** — Carbon presented four times at the ASGCT 27th Annual Meeting and expanded its board and scientific advisory board

## Achievements

- Founded Carbon Biosciences and raised a $38 million Series A to build a non-AAV, parvovirus-based gene therapy platform
- Was the first employee at Solid Biosciences and helped build its disease-focused gene therapy business model
- Assembled a syndicate including Agent Capital, Longwood Fund, Astellas Venture Management, the Cystic Fibrosis Foundation, Solasta Ventures, UTokyo IPC and Camford Capital
- Advanced a lead cystic fibrosis program (CGT-001) based on the CBN-1000 vector, with a cardiac vector (CBN-1100) showing payloads up to 5.9 kb
- Author of numerous peer-reviewed articles on Duchenne muscular dystrophy and stem cell biology

## Latest updates

- **2024-05** — Carbon Biosciences presented four times at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting.
- **2024-05** — Carbon announced new appointments to its Board of Directors and Scientific Advisory Board, including Carol Ann Satler and Lloyd Klickstein.

## Links

- LinkedIn: http://www.linkedin.com/in/joel-schneider-6101a713

---

Profile page: https://yespress.io/joel-schneider
Published by YesPress — https://yespress.io
Last updated: 2026-07-16